Maximus, Inc. $MMS Shares Bought by New Vernon Capital Holdings II LLC

Key Points

• New Vernon Capital Holdings II LLC significantly increased its stake in Maximus, Inc. by 6,719%, acquiring 195,364 shares worth approximately $13.3 million.
• Maximus reported $2.16 earnings per share, surpassing analysts' expectations of $1.39, alongside a revenue of $1.35 billion for the recent quarter.
• The company recently announced a quarterly dividend of $0.30 per share, with a dividend yield of 1.4%, reflecting a payout ratio of 22.10%.

New Vernon Capital Holdings II LLC increased its position in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 6,719.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 195,364 shares of the health services provider's stock after buying an additional 192,499 shares during the period. New Vernon Capital Holdings II LLC owned about 0.35% of Maximus worth $13,322,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MMS. AQR Capital Management LLC increased its stake in shares of Maximus by 177.2% during the first quarter. AQR Capital Management LLC now owns 1,173,329 shares of the health services provider's stock worth $79,341,000 after buying an additional 750,031 shares during the period. Fuller & Thaler Asset Management Inc. increased its stake in shares of Maximus by 40.0% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,729,305 shares of the health services provider's stock worth $117,921,000 after buying an additional 494,372 shares during the period. SG Capital Management LLC acquired a new position in Maximus in the fourth quarter valued at approximately $30,285,000. Reinhart Partners LLC. boosted its holdings in Maximus by 65.4% in the first quarter. Reinhart Partners LLC. now owns 911,511 shares of the health services provider's stock valued at $62,156,000 after purchasing an additional 360,365 shares in the last quarter. Finally, Boston Partners acquired a new position in Maximus in the first quarter valued at approximately $20,983,000. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus Stock Performance

NYSE:MMS traded up $0.07 during trading hours on Wednesday, reaching $87.49. 332,002 shares of the company's stock were exchanged, compared to its average volume of 567,653. The firm has a market capitalization of $4.93 billion, a price-to-earnings ratio of 16.11 and a beta of 0.61. The company has a 50-day moving average of $78.88 and a 200 day moving average of $72.69. The company has a quick ratio of 2.27, a current ratio of 2.27 and a debt-to-equity ratio of 0.91. Maximus, Inc. has a 1-year low of $63.77 and a 1-year high of $93.94.

Maximus (NYSE:MMS - Get Free Report) last announced its earnings results on Thursday, August 7th. The health services provider reported $2.16 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.77. Maximus had a net margin of 5.83% and a return on equity of 24.44%. The business had revenue of $1.35 billion during the quarter, compared to analysts' expectations of $1.29 billion. During the same period in the prior year, the company earned $1.74 earnings per share. The business's revenue was up 2.5% compared to the same quarter last year. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. Research analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Sunday, August 31st. Shareholders of record on Friday, August 15th were given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend was Friday, August 15th. Maximus's dividend payout ratio (DPR) is presently 22.10%.

Wall Street Analyst Weigh In

MMS has been the subject of a number of research analyst reports. Wall Street Zen downgraded Maximus from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Zacks Research raised Maximus from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Strong Buy" and a consensus price target of $90.00.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.